Recursion Pharmaceuticals Statistics

Total Valuation

RXRX has a market cap or net worth of $2.46 billion. The enterprise value is $1.88 billion.

Market Cap	2.46B
Enterprise Value	1.88B

Important Dates

The last earnings date was Wednesday, November 5, 2025, before market open.

Earnings Date	Nov 5, 2025
Ex-Dividend Date	n/a

Share Statistics

RXRX has 521.26 million shares outstanding. The number of shares has increased by 63.30% in one year.

Current Share Class	514.90M
Shares Outstanding	521.26M
Shares Change (YoY)	+63.30%
Shares Change (QoQ)	+7.10%
Owned by Insiders (%)	3.25%
Owned by Institutions (%)	60.82%
Float	503.59M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	43.24
Forward PS	29.86
PB Ratio	2.21
P/TBV Ratio	4.36
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	42.98
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.60, with a Debt / Equity ratio of 0.08.

Current Ratio	4.60
Quick Ratio	4.40
Debt / Equity	0.08
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-294.74

Financial Efficiency

Return on equity (ROE) is -91.06% and return on invested capital (ROIC) is -51.24%.

Return on Equity (ROE)	-91.06%
Return on Assets (ROA)	-42.04%
Return on Invested Capital (ROIC)	-51.24%
Return on Capital Employed (ROCE)	-57.46%
Revenue Per Employee	$54,611
Profits Per Employee	-$894,429
Employee Count	800
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	-149,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -33.94% in the last 52 weeks. The beta is 0.94, so RXRX's price volatility has been similar to the market average.

Beta (5Y)	0.94
52-Week Price Change	-33.94%
50-Day Moving Average	5.13
200-Day Moving Average	5.33
Relative Strength Index (RSI)	50.53
Average Volume (20 Days)	24,712,211

Short Selling Information

The latest short interest is 145.66 million, so 27.94% of the outstanding shares have been sold short.

Short Interest	145.66M
Short Previous Month	128.59M
Short % of Shares Out	27.94%
Short % of Float	28.92%
Short Ratio (days to cover)	2.42

Income Statement

In the last 12 months, RXRX had revenue of $43.69 million and -$715.54 million in losses. Loss per share was -$1.78.

Revenue	43.69M
Gross Profit	-503.45M
Operating Income	-715.05M
Pretax Income	-715.69M
Net Income	-715.54M
EBITDA	-637.88M
EBIT	-715.05M
Loss Per Share	-$1.78

Full Income Statement

Balance Sheet

The company has $659.84 million in cash and $82.37 million in debt, giving a net cash position of $577.46 million or $1.11 per share.

Cash & Cash Equivalents	659.84M
Total Debt	82.37M
Net Cash	577.46M
Net Cash Per Share	$1.11
Equity (Book Value)	1.05B
Book Value Per Share	2.13
Working Capital	559.00M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$441.17 million and capital expenditures -$6.52 million, giving a free cash flow of -$447.69 million.

Operating Cash Flow	-441.17M
Capital Expenditures	-6.52M
Free Cash Flow	-447.69M
FCF Per Share	-$0.86

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1,636.68%
Pretax Margin	-1,638.15%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RXRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-63.30%
Shareholder Yield	-63.30%
Earnings Yield	-29.14%
FCF Yield	-18.23%

Dividend Details

Analyst Forecast

The average price target for RXRX is $7.25, which is 53.93% higher than the current price. The consensus rating is "Buy".

Price Target	$7.25
Price Target Difference	53.93%
Analyst Consensus	Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RXRX has an Altman Z-Score of 0.75 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.75
Piotroski F-Score	2